Формы ренальной остеодистрофии


Ю.С. Милованов, Л.Ю. Милованова, Л.В. Козловская

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждаются клинико-патогенетические варианты ренальной остеодистрофии и подходы к их лечению.

Литература


1. National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am. J. Kidney Dis. 2003 (suppl. 3); 42: S1–S202.
2. Нефрология: национальное руководство / Под ред. Н.А. Мухина. М.: ГЕОТАР-Медиа. 2009;616–628.
3. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D. Нефрол. диал. 2004; 2(6):116–127.
4. Yajima A., Inaba M., Tominaga Y. et al. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 2008;74: 775–781.
5. KDIGO. Clinical Practice for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int. 2009; 76 (Suppl): 113–120
6. Brossard J.H., Lepage R., Cardinal H. et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin. Chem. 2000; 46: 697–703
7. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am. J. Kidney Dis. 2000; 35: 1226–1237.
8. Рожинская Л.Я. Вторичный гиперпаратиреоз и почечный остеопатии при хронической почечной недостаточности. Нефрол. диал. 2000; 4(2): 241–247.
9. Шило В.Ю. Гиперпаратиреоз и кальцимиметики. Нефрол. диал. 2009; 3(11): 144–233.
10. Земченков А.Ю., Герасимчук Р.П. Активаторы рецепторов витамина D и сосудистая кальцификация (обзор литературы). Нефрол. диал. 2009; 4(11): 276–292.
11. Danese M.D., Belozeroff V., Smirnakis K. et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1423–1429.
12. Sprague S.M., Moe S.M. Clinical manifestations and pathogenesis of dialysisrelated amyloidosis. Semin. Dial. 1996; 9: 360–369.
13. Gal R., Korzets A., Schwartz A. et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis populations. Arch. Pathol. Lab. Med. 1994; 118: 718–721.
14. Portale A.A. Blood calcium, phosphorus, and magnesium, in Favus M.J. (ed): Primer on the Metabilic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, PA, Lippincott, Williams &Wilkins;. 1999;115–118.
15. Stehman-Breen C.O., Sherrard D.J., Alem A.M., Gillen D.L., Heckbert S.R., Wong C.S., Ball A., Weiss N.S. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58: 2200–2205.
16. Coco M., Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am. J. Kidney Dis. 2000; 36: 1115–1121.
17. Alem A.M., Sherrard D.J., Gillen D.L. et al. Increased risk of hip fracture among patients with end-stage renal dis. Kidney Int. 2000; 58: 396–399.
18. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрол. диал. 2002; 2(4):113–117.
19. Yamazaki Y. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008; 23: 1509–1518.
20. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperperathyroidism in a haemodialysis patient. Nephrol. Dial. Transplant. Plus. 2008; 1: 148–150.
21. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. Curr. Vasc. Pharmacol. 2008; 6: 148–153.
22. Cozzolino M., Brandenburg V. Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the “U”. Clin. Nephrol. 2009; 71(6): 593–601.
23. Lund R.J., Andress D.L., Amdahl M. et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol. 2010; 31(2): 165–170.
24. Schumock G.T., Walton S.M., Lee T.A. et al. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin Pract. 2011; 117(2): c151–c159.
25. Nuijten M., Andress D.L., Marx S.E. et al. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig. 2010; 30(8): 545–557.
26. de Zeeuw D., Agarwal R., Amdahl M. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet.
2010; 376: 1543–1551.
27. Ohashi K., Hara M., Kawai R. et al. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. Kidney Int. 1992; 41: 1646–1652.
28. Jadoul M., Malghem J., Vande Berg B. et al. Ultasonographic datertion of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol. Dial. Transplant. 1993; 8: 1104–1109.
29. Zingraff J., Noel L.H., Bardin T. et al. Beta 2-microglobulin amyloidosis: A sternoclavicular joint biopsy study in hemodialysis patients. Clin. Nephrol. 1990; 33: 94–97.
30. Fliser D., Kollerits B., Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600–2608.
31. Franceschi R.T., Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J. Cell. Biochem. 2003; 88: 446–454.
32. Fukagawa M., Yumita S., Akizawa T. et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol. Dial. Transplant. 2008; 23: 328–335.
33. Cravaca F., Fernandez M.A., Ruiz-Calero R. et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol. Dial. Transplant. 1998; 13: 2605–2611.
34. Ambuhl P.M., Meier D., Wolf B. et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am. J. Kidney Dis. 1999; 34: 875–883.
35. Torres A., Rodrigues A.P., Cocepcion M.T. et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentration. Nephrol. Dial. Transplant. 1998; 13 (suppl. 3): 94–97.
36. Dumoulin G., Hory B., Nguyen N.U. et al. Lack of evidence that cyclosporine treatment impairs calcium-phospharus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplant. 1995; 59: 1690–1694.
37. Lukert B.P., Raisz L.G. Glucocorticoid-indused osteoporosis: Pathogenesis and management. Ann. Inrern. Med. 1990; 112: 352–364.
38. Dempster D.W. Bone histomorhometry in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 1989; 4: 137–141.
39. Grotz W.H., Mundinger F.A., Rasenack J. et al. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol. Dial. Transplant. 1995; 10: 2096–2100.
40. Cueto-Manzano A.M., Konel S., Hutchison A.J. et al. Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int. 1999; 55: 2021–2029.
41. Aroldi A., Tarantino A., Montagnino G. et al. Effect of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplant. 1997; 63: 380–386.
42. Ficat R.P. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J. Bone Joint Surg. Br. 1985; 67: 3–9.
43. Hasselblad V., Hedges L.V. Meta-analysis of screening and diagnostic tests. Psycho. Bull. 1995; 117: 167–178.
44. Carano A., Teitelbaum S.L., Konsek J.D. et al. bisphosphonates directly inhibit the bone resorption activity of isolated avain osteoclasts in vitro. J. Clin. Invest. 1990; 85: 456–461.
45. Grotz W.H., Rump L.C., Niessen A. et al. Traatment of osteopenia and osteoporosis after kidney transplantation. Transplant. 1998; 66:1004–1008.


Об авторах / Для корреспонденции


Милованов Ю.С. – ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н. E-mail: yuriymilovanov@mail.ru;
Милованова Л.Ю. – научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, к.м.н.;
Козловская Л.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.


Похожие статьи


Бионика Медиа